Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present at Upcoming Investor Conferences

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

BIO-Europe 2021, Virtual

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa